Generic pharmaceutical company Accord Healthcare Inc, part of India-based Intas Pharmaceuticals, announced on Tuesday that it has launched Clomiphene tablets, the generic equivalent of CLOMID (clomiphene citrate), in the United States.
The new product is intended for the treatment of ovulatory dysfunction in women desiring pregnancy.
Chrys Kokino, president of Accord Healthcare North America, said: "Our primary focus will always be to provide access to high quality, essential medicines for all patients and ensure a positive patient experience. We are pleased to be able to provide Accord Clomiphene tablets as another option for those women who may need this medication. We look forward to continuing to launch and support important products specifically focused on women's healthcare."
Accord Healthcare launches Clomiphene tablets in US market
Zentiva receives ESG Transparency Award 2025
Galmed Pharmaceuticals reports topline results for combination of Aramchol, Stivarga and metformin
Ingenus Pharmaceuticals' generic equivalent to Premarin receives US FDA approval
EirGenix signs second global exclusive licensing deal with Sandoz
Padagis invests USD36m to expand manufacturing in Minneapolis
Newbury Pharmaceuticals gains Danish approval for generic ivermectin cream
Esperion settles with Dr. Reddy's Laboratories on NEXLETOL and NEXLIZET generics
Mint Pharmaceuticals forms distribution partnership with Bayer Canada
Padagis collaborates with The Naloxone Project to address opioid overdose crisis
Zentiva announces sale from Advent to GTCR
Biocon's first US manufacturing facility inaugurated in Cranbury, New Jersey
Amneal's risperidone extended-release injectable suspension approved by US FDA
First FDA acceptance to waive clinical efficacy studies for monoclonal antibody biosimilars